CHDR and Leiden University Medical Center gladly announce the successful start of the in-depth profiling of patients with cutaneous T cell lymphoma. While this is a very rare condition, the strong setup between the long-standing clinical expertise at LUMC, department of dermatology (Prof. M.H. Vermeer, dr K. Quint) and trial methodology from CHDR, novel readouts including lipidomics (prof Rissmann) and oncology (dr Bosch) join forces to unravel mechanisms of this disease. More specifically, the interaction between microbiome, skin barrier and the cutaneous condition will be elucidated. By taking skin biopsies of the lesions, a full profile of the patients will be established. The first patient was included on April 3rd (first patient first visit) and since this is the 4th project in this disease, the team is very enthusiastic about the successful program in this indication. Importantly, patient reported outcomes will also be elucidated at home with CHDR’s Trial@home platform.
This trial will be part of the public NWA-ORC project “Next generation immunodermatology (NGID)”, which LUMC/CHDR/Leiden University lead. Read more on the grant here.
